The Effect of Non Steroidal Anti-Inflammatory Drugs (Naproxen Sodium) on Endometrial Stromal Cell Proliferation

2000 ◽  
Vol 74 (3) ◽  
pp. S186-S187
Author(s):  
F Attar ◽  
A Bilir ◽  
S Bulgurcuoglu ◽  
F Oncu ◽  
R Has ◽  
...  
2002 ◽  
Vol 266 (4) ◽  
pp. 223-228 ◽  
Author(s):  
Seung Yup Ku ◽  
Y. M. Choi ◽  
Chang Suk Suh ◽  
Seok Hyun Kim ◽  
Jung Gu Kim ◽  
...  

Endocrine ◽  
2016 ◽  
Vol 53 (2) ◽  
pp. 595-606 ◽  
Author(s):  
Shuangbo Kong ◽  
Xue Han ◽  
Tongtong Cui ◽  
Chan Zhou ◽  
Yufei Jiang ◽  
...  

2001 ◽  
Vol 26 (3) ◽  
pp. 224-228 ◽  
Author(s):  
G. P. RILEY ◽  
M. COX ◽  
R. L. HARRALL ◽  
S. CLEMENTS ◽  
B. L HAZLEMAN

The purpose of this study was to investigate the effects of some commonly used non-steroidal anti-inflammatory drugs (NSAIDs) on human tendon. Explants of human digital flexor and patella tendons were cultured in medium containing pharmacological concentrations of NSAIDs. Cell proliferation was measured by incorporation of 3H-thymidine and glycosaminoglycan synthesis was measured by incorporation of 35S-Sulphate. Diclofenac and aceclofenac had no significant effect either on tendon cell proliferation or glycosaminoglycan synthesis. Indomethacin and naproxen inhibited cell proliferation in patella tendons and inhibited glycosaminoglycan synthesis in both digital flexor and patella tendons. If applicable to the in vivo situation, these NSAIDs should be used with caution in the treatment of pain after tendon injury and surgery.


Author(s):  
J.C.S. Breitner ◽  
C.G. Lyketsos

The Alzheimer’s Disease Anti-inflammatory Prevention Trial was a placebo-controlled three-arm pharmaco-prevention trial of the non-steroidal anti-inflammatory drugs naproxen sodium and celecoxib for prevention of incident Alzheimer’s disease (AD) dementia in older (aged 70 and over) adults. Although subjects were at increased risk of symptoms because of a firstdegree family history, they were meant to be cognitively healthy at enrollment. ADAPT encountered several problems that resulted in the termination of its treatments after only two years on average. Interim results were complex but potentially interesting. In the end, however, the results were null. We describe the complications that prevented ADAPT from achieving conclusive results, and suggest that these could have been avoided if the trial design and execution had been better guided by preliminary data. We believe such data should be available before beginning further ambitious phase III trials of this sort, and we suggest a broad method by which such data can be accumulated with reasonable economy.


Sign in / Sign up

Export Citation Format

Share Document